Resurgent Financial Advisors LLC Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX

Resurgent Financial Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the fourth quarter, Holdings Channel reports. The firm purchased 1,149 shares of the pharmaceutical company’s stock, valued at approximately $521,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Eagle Bay Advisors LLC bought a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $29,000. IMG Wealth Management Inc. raised its holdings in Vertex Pharmaceuticals by 277.8% during the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 50 shares during the last quarter. Colonial Trust Co SC raised its holdings in Vertex Pharmaceuticals by 118.8% during the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 38 shares during the last quarter. Ares Financial Consulting LLC bought a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $33,000. Finally, Archer Investment Corp raised its holdings in Vertex Pharmaceuticals by 89.7% during the 4th quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company’s stock valued at $34,000 after buying an additional 35 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $445.04 on Friday. The stock has a market cap of $112.95 billion, a PE ratio of 26.40, a price-to-earnings-growth ratio of 1.86 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $507.92. The firm’s 50-day simple moving average is $437.19 and its two-hundred day simple moving average is $452.38.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The company had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $2.99 billion. During the same period in the prior year, the firm posted $4.06 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on VRTX. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 30th. Maxim Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 price objective for the company in a report on Wednesday, March 18th. Citigroup upped their price objective on shares of Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $590.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Finally, Bank of America upped their price objective on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $555.91.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex announced new data on CASGEVY showing clinical benefits in patients ages 5 and older with severe sickle cell disease or transfusion-dependent beta thalassemia, including pediatric data consistent with the therapy’s profile in older patients. The company also said it is making additional global regulatory submissions, which could expand the drug’s commercial opportunity. Article Title
• Positive Sentiment: Several recent items point to supportive Wall Street views, including a “Moderate Buy” consensus and multiple higher price targets, suggesting analysts still see upside despite the stock’s recent strength.
• Neutral Sentiment: Vertex presented at the Goldman Sachs Global Healthcare Conference, but no major new financial guidance or pipeline surprise was highlighted in the available summary. Article Title
• Neutral Sentiment: A senior executive sold shares under a pre-arranged 10b5-1 plan. While this can draw attention, the sale appears routine rather than a sign of negative business developments. Article Title
• Negative Sentiment: Erste Group trimmed its FY2027 EPS estimate for Vertex slightly, which may have limited enthusiasm a bit, though the change was modest and the outlook remains above current-year consensus. Article Title

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Joy Liu sold 1,104 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the sale, the executive vice president directly owned 20,729 shares in the company, valued at $8,810,239.58. The trade was a 5.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 1,745 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $450.00, for a total transaction of $785,250.00. Following the completion of the sale, the chief marketing officer owned 21,015 shares of the company’s stock, valued at $9,456,750. This represents a 7.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,133 shares of company stock worth $4,973,106 over the last three months. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.